/Tag:FDA

FDA

Yes, DEA, there’s an ADHD Med Shortage

By | 2016-11-20T07:53:44+00:00 January 1st, 2012|Categories: ADD, ADHD, Medication, News|Tags: , , , , , , , , |

The FDA says there's a shortage of ADHD medications. They've put stimulant medications on their official shortage list. The DEA says there's no shortage. I've been taking Adderall since I was 23. I'm now, um, considerably older. I tried to get my Adderall prescription filled a couple of months ago. For the first time, I was [...]

Comments Off on Yes, DEA, there’s an ADHD Med Shortage

New study on the effectiveness of St. John’s Wort

By | 2016-10-05T06:46:13+00:00 October 9th, 2008|Categories: Depression/Anxiety, Medication, Research|Tags: , , , , , , , , |

Across 29 studies, St. John's Wort was found to be more effective than placebo and just as effective as Prozac in treating mild to moderate depression. However, it should be noted that the researchers stated that some of the smaller German studies may have had "over-optimistic results". Keep in mind that in some countries, like Germany, [...]

Comments Off on New study on the effectiveness of St. John’s Wort

Article on Secretin clinical trial for Autism

By | 2016-10-05T06:46:13+00:00 June 27th, 2008|Categories: Autism, Medication, Research|Tags: , , , , , , , , , |

In 2003, we were a site that participated in conducting a clinical trial for Secretin. The purpose of the study was to determine safety and efficacy of Secretin versus placebo in the treatment of Autism symptoms.  Unfortunately, the study results found that there was no difference in symptom change between children on Secretin and those on placebo.   Here's an article on [...]

Comments Off on Article on Secretin clinical trial for Autism

Results from Phase II study with new ADHD drug

By | 2016-10-05T06:46:13+00:00 June 20th, 2008|Categories: ADHD, Medication, Research|Tags: , , , , , , , , , |

ABT-894 is a drug that is currently undergoing clinical trials for possible approval by the FDA for the treatment of adult ADHD.  Drugs have to undergo specific study phases and must demonstrate safety and efficacy before they are approved by the FDA.  ABT-894 is a neuronal nictotinic receptor (NNR) modulator.  NNRs modulate the release of neurotransmitters such as acetylcholine and [...]

Comments Off on Results from Phase II study with new ADHD drug

FDA approves 3 new dosage strengths for Vyvanse

By | 2016-10-05T06:46:15+00:00 January 3rd, 2008|Categories: ADHD, Medication|Tags: , |

Vyvanse (lisdexamfetamine dimesylate) will now be offered in 20mg, 40mg and 60mg strengths in addition to 30mg, 50mg and 70mgs. Vyvanse is a stimulant that is FDA-approved for the treatment of ADHD. The new dosages should be available sometime before the end of March 2008. http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-22012011.htm

Comments Off on FDA approves 3 new dosage strengths for Vyvanse